{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:50Z","timestamp":1761871490540,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clml.2020.07.012","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T22:39:48Z","timestamp":1595630388000},"page":"e944-e946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol"],"prefix":"10.1016","volume":"20","author":[{"suffix":"IV","given":"William Paul","family":"Skelton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-667X","authenticated-orcid":false,"given":"Elyce","family":"Turba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.07.012_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4161\/cbt.9.8.11264","article-title":"Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types","volume":"9","author":"Kaplan-Lefko","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2020.07.012_bib2","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-10-0631","article-title":"A\u00a0first-in-human study of conatumumab in adult patients with advanced solid tumors","volume":"16","author":"Herbst","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.07.012_bib3","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1002\/cncr.28353","article-title":"TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b\/2 trial","volume":"119","author":"Fuchs","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.07.012_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejca.2011.12.008","article-title":"First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I\/II open-label and double-blind study","volume":"48","author":"Demetri","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.07.012_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JTO.0b013e31827ce554","article-title":"A\u00a0randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"8","author":"Paz-Ares","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clml.2020.07.012_bib6","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mds142","article-title":"A\u00a0randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"23","author":"Kindler","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.07.012_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A\u00a0randomized, placebo-controlled phase\u00a02\u00a0study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.07.012_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma","volume":"147","author":"Dickinson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.07.012_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","article-title":"Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Hu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.07.012_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A\u00a0phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: SWOG S0517","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.07.012_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2014.04.028","article-title":"Apo2L\/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity","volume":"26","author":"Graves","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.07.012_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor\u2013based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:27Z","timestamp":1761870927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020303736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2152265020303736"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}